41 results
8-K
EX-99.2
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
, and expires (i) three months after the Company delivers to Genentech the IND filing package for a product incorporating the first molecule; or (ii … ) if an additional extension payment is provided, four months after the Company delivers to Genentech the Phase I data package for such product. If Genentech
8-K
jz6x376386v4nwhdxk
21 Dec 21
Other Events
8:00am
8-K
EX-10.1
bnll2tijt6 pbbe
16 Aug 21
Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants
7:21am